FLT3 and acute myeloid leukemia: Data obtained in a phase I study, which sequentially administered decitabine and midostaurin in newly diagnosed elderly or relapse /refractory adult patients with AML (13% with FLT3 mutations), showed in the intention to treat analysis that 57% of patients achieved stable disease and 25% had a complete haematological response [10].